Up­dat­ed: RA Cap­i­tal and Soft­Bank head up the lat­est nine-fig­ure crossover, this time for Ven­tus. Will an IPO soon fol­low?

A biotech pre­vi­ous­ly backed by Ver­sant and GV is un­veil­ing its newest fi­nanc­ing round, com­ing with a slate of blue-chip in­vestors that could sig­nal an IPO in the near fu­ture.

Ven­tus Ther­a­peu­tics closed a $140 mil­lion Se­ries C on Wednes­day morn­ing, a round led by the sec­ond Soft­Bank Vi­sion Fund and RA Cap­i­tal. The biotech said in a press re­lease the mon­ey will large­ly be used to scale its sec­ond plat­form and help push its lead drug pro­gram clos­er to the clin­ic.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER